Asthma Clinical Trial
— AVICAOfficial title:
Acetaminophen vs. Ibuprofen in Children With Asthma
The Acetaminophen Versus Ibuprofen in Children with Asthma study will test the primary hypothesis that in preschool children 12-59 months of age with persistent asthma on standardized asthma therapy, the number of asthma exacerbations requiring systemic corticosteroids will be more frequent in children randomized to receive acetaminophen as compared to those randomized to receive ibuprofen on an as needed basis for fevers and pain.
Status | Completed |
Enrollment | 300 |
Est. completion date | April 2015 |
Est. primary completion date | April 2015 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 12 Months to 59 Months |
Eligibility |
Inclusion Criteria: - 12-59 months of age. - If the child is not currently taking long-term asthma controller therapy (meaning that the child has taken no inhaled corticosteroid or leukotriene receptor antagonist medication whatsoever over the past 6 months), then one of the following criteria must be met: - Daytime asthma symptoms more than two days per week (average over the past 4 weeks), - At least one nighttime awakening from asthma (over the past 4 weeks), - Two or more asthma exacerbations requiring systemic corticosteroids in the previous 6 months, - Four or more wheezing episodes in the previous 12 months. - If the child is currently taking long-term asthma controller therapy (meaning that the child has taken daily or intermittent/as-needed inhaled corticosteroid or leukotriene receptor antagonist over the past 6 months), then one of the following criteria must be met: - Taking inhaled corticosteroid or leukotriene receptor antagonist for more than 3 months (or more than 90 days) out of the previous 6 months (or 180 days), - Daytime asthma symptoms more than two days per week (average over the past 4 weeks), - More than one nighttime awakening from asthma (over the past 4 weeks), - Two or more asthma exacerbations requiring systemic corticosteroids in the previous 12 months, - Four or more wheezing episodes in the previous 12 months. - Up to date with immunizations, including varicella (unless the subject has already had clinical varicella). - Willingness to provide informed consent by the child's parent or guardian. Exclusion Criteria: - Allergic reaction to the study medications or any component of the study drugs, including (but not limited to) urticaria, rash, angioedema, or hypotension following delivery, - Chronic medical disorders that could interfere with drug metabolism/excretion (for instance chronic hepatic, biliary, or renal disease), - Chronic medical disorders that may increase the risk of drug-related injury, including (but not limited to): - Osteogenesis imperfecta (increased risk of bone demineralization/fracture with corticosteroid therapy), - Crohn's disease, ulcerative colitis, juvenile rheumatoid arthritis, clotting disorders, or Factor deficiency (increased risk of bleeding with corticosteroid therapy), - G6PD deficiency (increased risk of hemolytic anemia with acetaminophen use), - Phenylketonuria (potential for aspartame exposure with study interventions), - Seizure disorder treated with anticonvulsants (risk of acetaminophen toxicity with carbamazepine), or - History of clotting disorders or Factor deficiency (increased risk of bleeding with corticosteroids), - Co-morbid disorders associated with wheezing including (but not limited to) immune deficiency disorders, cystic fibrosis, aspiration, clinically-relevant gastroesophageal reflux, tracheomalacia, congenital airway anomalies (clefts, fistulas, slings, rings), bronchiectasis, bronchopulmonary dysplasia, and/or history of premature birth before 35 weeks gestation, - Significant developmental delay/failure to thrive, defined as 5th percentile for height and/or weight or crossing of two major percentile lines during the last year for age and sex, - History of a near-fatal asthma exacerbation requiring intubation or assisted ventilation, - No primary medical caregiver (e.g., a nurse practitioner, physician assistant, physician, or group medical practice such as a hospital-based clinic) whom the subject can contact for primary medical care, - Three or more hospitalizations in the previous 12 months for wheezing or respiratory illnesses, - Treatment with 5 or more courses of systemic corticosteroids (oral, intramuscular or intravenous) in the past 6 months, - Current use of higher than step 2 NAEPP asthma guideline therapy - If receiving allergy shots, change in the dose within the past 3 months. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | Emory University | Atlanta | Georgia |
United States | Children's Hospital Boston | Boston | Massachusetts |
United States | Children's Hospital, Boston | Boston | Massachusetts |
United States | University of Virginia Health System | Charlottesville | Virginia |
United States | Children's Memorial Hospital | Chicago | Illinois |
United States | Rush University Medical Center/Stroger Hospital | Chicago | Illinois |
United States | Rainbow Babies and Children's Hospital, Case Western Reserve University | Cleveland | Ohio |
United States | National Jewish Health | Denver | Colorado |
United States | University of Wisconsin-Madison | Madison | Wisconsin |
United States | Children's Hospital & Research Center Oakland | Oakland | California |
United States | Children's Hospital of Pittsburgh of UPMC | Pittsburgh | Pennsylvania |
United States | UCSF Benioff Children's Hospital | San Francisco | California |
United States | St. Louis Children's Hospital | St. Louis | Missouri |
United States | University of Arizona College of Medicine | Tucson | Arizona |
United States | Wake Forest University Health Sciences | Winston-Salem | North Carolina |
Lead Sponsor | Collaborator |
---|---|
Milton S. Hershey Medical Center | National Heart, Lung, and Blood Institute (NHLBI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | exacerbation frequency | the number of asthma exacerbations requiring systemic corticosteroids | 48 week treatment period | No |
Secondary | asthma control days | proportion of study days on which asthma was controlled, measured by electronic diary | 48 week treatment period | No |
Secondary | asthma rescue medication use | average albuterol rescue use per week, measured by electronic diary | 48 week treatment period | No |
Secondary | health care utilization | frequency of unscheduled physician visits, emergency department visits or hospitalizations for asthma | 48 week treatment period | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|